Peregrine Pharma (PPHM) Reports In-Line Q3 Loss of 13c/Share

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $3.28 million versus the consensus estimate of $2.12 million.

For earnings history and earnings-related data on Peregrine Pharmaceuticals, Inc. (PPHM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Radnostix revenue falls 27% amid product recalls and FDA actions
• SanDisk unveils long-term growth strategy at 2026 Investor Day; Shares surge 12%